EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Utility‐Based Dose Optimization Approaches for Multiple‐Dose Randomized Trial Designs Accounting for Multiple Endpoints

Gina D'Angelo iD, Guannan Chen iD, Di Ran iD

Pharmaceutical Statistics · 2025-11 · 24 (6)

DOI: 10.1002/pst.70044 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pharmaceutical Statistics, online erschienen am 20.10.2025. Verfasst von Gina D'Angelo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Biometrics, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA. Hauptthemen laut MEDLINE: Research Design, Randomized Controlled Trials as Topic, Endpoint Determination, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The initiation of dose optimization has driven a paradigm shift in oncology clinical trials to determine the optimal biological dose (OBD). Early‐phase trials with randomized doses can facilitate additional investigation of the identified OBD in targeted populations by incorporating safety, efficacy, and biomarker data. To support dose comparison in such settings, we propose to extend the utility score–based approach (U‐MET) to account for multiple endpoints and doses. The utility‐based dose optimization approach for multiple‐dose randomized trial designs accounting for multiple (≤ 3) endpoints and doses (U‐MET‐m) extends the U‐MET, using a utility score to account for multiple endpoints jointly (e.g., toxicity‐efficacy trade‐off). When there are > 3 endpoints, assigning weights jointly is quite complicated; therefore, we suggest an alternative approach with CUI‐MET (clinical utility index dose optimization approach for multiple‐dose randomized trial designs), which uses a utility index to account for multiple endpoints marginally. We demonstrate the relationship between U‐MET‐m and CUI‐MET to offer a guide in weight selection for U‐MET‐m when there are up to three endpoints. U‐MET‐m and (extended) CUI‐MET use Bayesian inference within a hypothesis framework to compare utility metrics across doses to identify the OBD. Here we describe simulation studies and present examples to compare both the U‐MET‐m and CUI‐MET designs with the empirical design. The U‐MET‐m design and CUI‐MET were shown to have satisfactory operating characteristics for selecting the OBD. Based on these findings, we recommend the U‐MET‐m with ≤ 3 endpoints and CUI‐MET with > 3 endpoints as the primary dose comparison approach to select the OBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignRandomized Controlled Trials as TopicEndpoint DeterminationAntineoplastic AgentsHumansDose-Response Relationship, Drug

Stichwörter der Autor:innen

CUI‐METU‐MET‐mdose optimizationdose randomizationoptimal biological doseutility

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Oncology Biometrics, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Department of Statistics, The George Washington University, Washington, Washington, DC, USA.

ORCID-Profile: Gina D'Angelo, Guannan Chen, Di Ran

Förderung

  • AstraZeneca

Zitieren

APA

D'Angelo, G., Chen, G., & Ran, D. (2025). Utility‐Based Dose Optimization Approaches for Multiple‐Dose Randomized Trial Designs Accounting for Multiple Endpoints. Pharmaceutical Statistics, 24(6). https://doi.org/10.1002/pst.70044

Vancouver

D'Angelo G, Chen G, Ran D. Utility‐Based Dose Optimization Approaches for Multiple‐Dose Randomized Trial Designs Accounting for Multiple Endpoints. Pharmaceutical Statistics. 2025;24(6). doi:10.1002/pst.70044

BibTeX
@article{DAngelo2025,
  author = {D'Angelo, Gina and Chen, Guannan and Ran, Di},
  title = {Utility‐Based Dose Optimization Approaches for Multiple‐Dose Randomized Trial Designs Accounting for Multiple Endpoints},
  journal = {Pharmaceutical Statistics},
  year = {2025},
  volume = {24},
  number = {6},
  doi = {10.1002/pst.70044}
}
Kostenlos starten →